Why the study?
Adverse events in COVID-19 are difficult to predict and risk stratification is encumbered by the need to protect healthcare workers. Artificial intelligence analysis of 12-lead intake ECGs could identify subtle myocardial involvement to predict complications.
Does artificial intelligence-powered analysis of 12-lead intake ECGs predict mortality or MACE in hospitalized COVID-19 patients?
Does artificial intelligence-powered analysis of 12-lead intake ECGs predict mortality or MACE in hospitalized COVID-19 patients?
AI analysis of intake 12-lead ECGs showed limited predictive ability for mortality and MACE in hospitalized COVID-19 patients, performing comparably to conventional demographic and comorbidity-based models.
Answers are grounded in this paper and cite their sources.
AI-ECG models flagged higher-risk COVID-19 patients; hypothesis-generating and requires prospective validation before any clinical adoption.
BACKGROUND: Adverse events in COVID-19 are difficult to predict. Risk stratification is encumbered by the need to protect healthcare workers. We hypothesize that artificial intelligence (AI) can help identify subtle signs of myocardial involvement in the 12-lead electrocardiogram (ECG), which could help predict complications. OBJECTIVE: Use intake ECGs from COVID-19 patients to train AI models to predict risk of mortality or major adverse cardiovascular events (MACE). METHODS: We studied intake ECGs from 1448 COVID-19 patients (60.5% male, aged 63.4 ± 16.9 years). Records were labeled by mortality (death vs discharge) or MACE (no events vs arrhythmic, heart failure [HF], or thromboembolic [TE] events), then used to train AI models; these were compared to conventional regression models developed using demographic and comorbidity data. RESULTS: A total of 245 (17.7%) patients died (67.3% male, aged 74.5 ± 14.4 years); 352 (24.4%) experienced at least 1 MACE (119 arrhythmic, 107 HF, 130 TE). AI models predicted mortality and MACE with area under the curve (AUC) values of 0.60 ± 0.05 and 0.55 ± 0.07, respectively; these were comparable to AUC values for conventional models (0.73 ± 0.07 and 0.65 ± 0.10). There were no prominent temporal trends in mortality rate or MACE incidence in our cohort; holdout testing with data from after a cutoff date (June 9, 2020) did not degrade model performance. CONCLUSION: Using intake ECGs alone, our AI models had limited ability to predict hospitalized COVID-19 patients' risk of mortality or MACE. Our models' accuracy was comparable to that of conventional models built using more in-depth information, but translation to clinical use would require higher sensitivity and positive predictive value. In the future, we hope that mixed-input AI models utilizing both ECG and clinical data may be developed to enhance predictive accuracy.
No takes yet. Share an insight, caveat, or question.
Sridhar et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: